Forensic science international. Genetics
March 1, 2025
Guillaume Drevin, O Hahn, N Picard et al.
2 citations
Interpreting postmortem concentrations of 3,4-Methylenedioxymethamphetamine (MDMA) remains challenging due to the wide range of reported results and the potential idiosyncratic nature of MDMA toxicity. Consequently, forensic pathologists often rely on a body of evidence to establish conclusions regarding the cause and the manner of death in death involving MDMA. Given these issues, implementing...
Disease-a-month : DM
March 1, 2025
Andrew M Farrar, Isabelle H Nordstrom, Kaitlyn Shelley et al.
7 citations
3,4-methylenedioxymethamphetamine (MDMA; commonly referred to as "ecstasy" or "molly") is a substituted amphetamine drug that is used recreationally for its acute psychoactive effects, including euphoria and increased energy, as well as prosocial effects such as increased empathy and feelings of closeness with others. Acute adverse effects can include hyperthermia, dehydration, bruxism, and...
Clinical Toxicology
March 1, 2025
Mirte J Zuidema, Elles Reimerink, Dena Akhoundzadeh et al.
1 citation
The persistent increase in the use of 3,4-methylenedioxymetamfetamine has led to an increase in emergency department presentations. Our aim was to study the most frequent reasons for admission to the intensive care unit of critically ill patients with 3,4-methylenedioxymetamfetamine intoxication and to describe their complications, management and outcome. This retrospective cohort study...
Clinical Toxicology
March 1, 2025
Joep J. J. Ouwerkerk, David M Wood, Alison M. Dines et al.
1 citation
This study hypothesized that 3,4-methylenedioxymetamfetamine intoxication presents with distinct clinical features and outcomes when combined with other substances of misuse, compared to mono-3,4-methylenedioxymetamfetamine intoxication. This study investigated the clinical presentation of acute mono-3,4-methylenedioxymetamfetamine intoxication, 3,4-methylenedioxymetamfetamine intoxication with...
Psychiatry Research
March 1, 2025
Stephanie L. Haft, Amanda E. Downey, Marissa Raymond-Flesch et al.
22 citations
A lack of diverse and representative participant samples in mental health intervention research perpetuates mental health disparities. This issue has become a salient concern in studies of psychedelic-assisted psychotherapy (PAT), which is emerging as a promising mental health intervention. This systematic review evaluates the reporting, representation, and analysis of participant...
The British Journal of Psychiatry
February 26, 2025
Ziad Saade, Alex S Keuroghlian
2 citations
This article explores the potential of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy to enhance exposure and response prevention in obsessive-compulsive disorder treatment. We discuss the mechanisms of MDMA, including fear extinction, psychological flexibility, and empathogenic effects that may improve adherence and efficacy, as well as highlighting important safety considerations...
Journal of Clinical Medicine
February 20, 2025
Shakila Meshkat, Taha Malik, Jennifer Swainson et al.
3 citations
Background/Objectives: Suicide accounts for 1.4% of global deaths, and the slow-acting nature of traditional treatments for suicide risk underscores the need for alternatives. Psychedelic therapies may rapidly reduce suicide risk. This systematic review evaluates impact of psychedelic therapies on suicide-related outcomes. Methods: A systematic search of MEDLINE, Embase, PsycINFO, and...
Nature Communications
February 12, 2025
Farid Aboharb, Pasha A. Davoudian, Ling-Xiao Shao et al.
19 citations
Psilocybin, ketamine, and MDMA are psychoactive compounds that exert behavioral effects with distinguishable but also overlapping features. The growing interest in using these compounds as therapeutics necessitates preclinical assays that can accurately screen psychedelics and related analogs. We posit that a promising approach may be to measure drug action on markers of neural plasticity in...
CPT: Pharmacometrics & Systems Pharmacology
February 1, 2025
Marilyn A. Huestis, William B Smith, Cathrine Leonowens et al.
3 citations
Midomafetamine (3,4-methylenedioxymethamphetamine [MDMA]) is under the U.S. Food and Drug Administration review for treatment of post-traumatic stress disorder in adults. MDMA is metabolized by CYP2D6 and is a strong inhibitor of CYP2D6, as well as a weak inhibitor of renal transporters MATE1, OCT1, and OCT2. A pharmacokinetic phase I study was conducted to evaluate the effects of food on MDMA...
Contemporary Clinical Trials Communications
February 1, 2025
Jessica L Maples-Keller, Boadie W Dunlop, Barbara O Rothbaum
5 citations
This article describes the rationale and the specific methods for an open label pilot trial of 100 mg MDMA in combination with massed exposure therapy for PTSD, a treatment which involves daily exposure therapy sessions for two weeks which has found to be effective. We review the need for novel PTSD treatments and the existing research on MDMA-assisted therapy, and then describe the rationale...
Current Psychiatry Reports
February 1, 2025
Jamarie Geller, Eric Whitney
3 citations
There is a mental health crisis affecting youth, and the utility of existing treatments is often limited by lack of effectiveness and tolerability. The aim of this review is to report on outcomes of clinical trials for psilocybin-assisted psychotherapy for adults with depression and MDMA-assisted psychotherapy for adults with post-traumatic stress disorder (PTSD) and discuss recommendations for...
CNS Spectrums
January 30, 2025
Steve O'Brien, David Nutt
5 citations
This chapter explores the complex and controversial path of MDMA-assisted therapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) and other behavioral disorders. It covers MDMA's history from research to recreation to medicine, the pivotal trials, and the challenges faced by researchers. Despite recent setbacks for the clinical application of MDMA, the chapter argues that it holds...
Addiction
January 30, 2025
Theodore Piper, Francesca Small, Michael Kelleher et al.
27 citations
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its quality; and to offer recommendations for...
Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention
January 21, 2025
Jennifer L. Schumann, Matthew Di Rago, Noel Woodford et al.
1 citation
Driving under the influence of alcohol and other drugs contributes significantly to road traffic crashes worldwide. This study explored trends of alcohol, methylamphetamine (MA), 3,4-methylenedioxy-N-methylamphetamine (MDMA) and Δ9-tetrahydrocannabinol (THC), in road crashes from 2010 to 2019 in Victoria, Australia. We conducted a cross-sectional analysis using data from the Victorian Institute...
Pharmaceuticals
January 19, 2025
Marco Bonaso, Letizia Biso, Benedetta Zucchini et al.
13 citations
Psychedelics, historically celebrated for their cultural and spiritual significance, have emerged as potential breakthrough therapeutic agents due to their profound effects on consciousness, emotional processing, mood, and neural plasticity. This review explores the mechanisms underlying psychedelics’ effects, focusing on their ability to modulate brain connectivity and neural circuit activity,...
Journal of Affective Disorders
January 15, 2025
Jia-Ru Li, Kuo-Tung Chiang, Yu-Chen Kao et al.
1 citation
Different study designs of psychedelic trials may impact the blinding and expectance, leading to biased treatment effects. This study aimed to examine the association between antidepressant efficacy and study designs in psychedelic trials. Six databases were systematically searched. Eligible trials were required to investigate the efficacy of psychedelics (psilocybin, lysergic acid diethylamide...
Journal of Education, Health and Sport
January 14, 2025
Wiktoria Podlasiewicz, Paweł Siudziński, Mateusz Łyko et al.
MDMA or 3,4- methylenedioxymethamphetamine is a psychoactive substance, exhibiting mild hallucinogenic properties, that became widely known as a recreational party drug. However, its ability in helping individuals access deeply rooted emotions has prompted significant interest in its potential applications within clinical practice. MDMA’s mechanism of action involves increasing the release of...
The American Journal of Bioethics
January 13, 2025
Jamie Beachy, Willa Hall, Chantelle Thomas et al.
2 citations
As research therapists with hundreds of hours of clinical experience supporting adults with PTSD in Phase 3 trials of MDMA assisted-therapy (MAT), we appreciate the opportunity to respond to this s...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
January 10, 2025
Dan Xu, Akifumi Eguchi, Rumi Murayama et al.
4 citations
3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy) is a widely abused recreational drug that has also gained interest for potential clinical applications in mental health. With the growing recognition of gut microbiota's role in mental health, this study examined whether repeated oral MDMA administration could affect gut microbiota in the small intestine, cecum, and colon of male rats. Repeated...
2025
Why do people seek a connection to something beyond the social dimensions of the world? Ecstatic experiences are often labelled religious, spiritual, mystical or even sacred. However, ecstasy is not just extraordinary; for many people throughout the world it is an ordinary part of daily life. The Handbook highlights the diverse individuals who have experienced ecstasy in the past and present...